Finn
MEDP Healthcare Services · CRO · Clinical trials · Biotech clients · Thesis updated October 25, 2026

Record new awards and a billion dollar buyback plan

01 Running thesis

Demand stays strong as buybacks return

Medpace continues to show clear demand for its focused clinical trial model. Net new business awards reached an all-time high of $873 million in the third quarter of 2026, up 10.6 percent from the prior year. This record level of new awards is the best early sign of future sales for a contract research organization.

The bull case centers on this sustained growth and a major return of capital to shareholders. Small and mid-sized drug developers still need help running full-service trials from Phase I through Phase IV. Crucially, the board authorized a new $1 billion share repurchase program in October 2026. This addresses a major open question from earlier in the year and provides a significant catalyst for earnings per share.

The bear case focuses on cycle risk, margins, and the timing of new revenue. Management deferred 2027 guidance to February because cancellations and award timing remain volatile. While recent cancellations were tied to drug failures rather than a lack of biotech funding, they still create short-term revenue pressure. Additionally, a large portion of revenue growth comes from lower-margin reimbursed expenses, which could pressure overall margins if that mix shifts.

Oct 2026▲Q3 2026 showed record net new business awards of $873 million. The board also authorized a new $1 billion share repurchase program, resolving capital return concerns.
Jul 2026▲Q2 2026 showed continued strong demand with net new business awards up 28.2 percent. The company resolved a major capital return question by resuming share repurchases, buying back $294.7 million of stock.
Apr 2026▲Q1 2026 showed strong operating momentum, with net new business awards up 23.7 percent and revenue up 26.5 percent. The offset was that Medpace made no share repurchases in the quarter.
Feb 2026▲The 2025 10-K showed net new business awards of $2.65 billion, revenue of $2.53 billion, and backlog above $3.0 billion. It also showed $912.9 million of share repurchases.
02 Business model

Paid to run the trial machine

Medpace helps drug, biotech, and medical device companies run clinical trials. It designs development plans, manages projects, handles regulatory work, monitors clinical sites, manages data, watches drug safety, and supports lab, imaging, and heart reading services.

Most contracts are fee-for-service. They are usually priced as fixed-fee work or by units of service. This means Medpace can make good money when it estimates trial costs well and keeps teams busy. It can also get hurt when a fixed-fee contract takes more work than planned.

Two numbers drive the model. Net new business awards show fresh signed work after cancellations. Backlog shows contracted work not yet recognized as revenue. The risk is that backlog is not cash in the bank. Customers can delay, cut, or cancel trials for reasons outside the control of the company.

03 Product portfolio

Where the trial work sits

Cash cow

Full-service clinical development

This is the core product. Medpace supports trials from Phase I through Phase IV, which lets clients use one main partner instead of many vendors.

Growth engine

Oncology trials

Cancer trials remain one of Medpace's key strengths. Oncology represents over half of overall bookings and continues to see strong demand.

Steady

Metabolic Disease trials

Metabolic was a major driver of recent growth, but awards have moderated as the mix shifts back to historical averages.

Growth engine

Central Nervous System trials

CNS work covers brain and nerve disorders. It remains a key focus area for clinical research.

Steady

Cardiology trials

Heart disease work is a long-running clinical research need. It provides a stable base of trial work.

Option

AVAI trials

AVAI means antiviral and anti-infective work. It is smaller than metabolic and oncology, but still part of the broad trial platform.

04 Business segments

One segment, several therapeutic areas

Oncology35%growing fast
Metabolic27%modest
Other13%declining
Central Nervous System11%growing fast
Cardiology8%declining
AVAI6%growing fast

Medpace reports one operating segment. The mix below uses recent revenue trends by therapeutic area, with oncology leading the current bookings growth.

05 Risk factors

What could break the story

Elevated trial cancellations

High impact · Medium odds

Cancellations remain a source of volatility and were toward the higher end of expectations in the third quarter. Even if driven by normal drug failures rather than funding issues, high cancellation rates reduce the revenue backlog.

We watchTrack customer cancellation rates and management comments on product failure trends.

Biotech funding turns down

High impact · Medium odds

Medpace depends heavily on small and mid-sized biopharma clients. If funding dries up, these clients may delay, shrink, or cancel trials.

We watchTrack biotech funding trends and quarterly net new business awards.

Margin mix gets worse

Medium impact · Medium odds

Reimbursed out-of-pocket expenses are a large part of growth. These pass-through costs can make revenue look bigger while adding less profit than service revenue. If service margins weaken, the growth headline may hide pressure underneath.

We watchWatch direct service costs, reimbursed out-of-pocket expenses, and operating margin.

AI and tech gap

Medium impact · Medium odds

The company added a risk about machine learning and generative AI in 2025. Poor controls could hurt quality, but too little investment could leave Medpace behind rivals using better trial tools.

We watchWatch for clear AI investment plans, control processes, and tech spending updates.
06 Quick answers

In one breath

What does Medpace do?

Medpace is a contract research organization. It helps drug, biotech, and medical device companies run clinical trials, from early human studies through post-market work.

How does Medpace make money?

Medpace charges clients for clinical development services. Contracts are often fixed-fee or based on units of service, and revenue is recognized as trial work is performed.

Why do investors watch net new business awards?

Net new business awards show new trial work won after cancellations. For Medpace, they are a key early signal of future revenue because awards can later move into backlog and then sales.

Why was the new buyback plan important?

Medpace paused its share repurchases early in 2026, raising concerns about capital returns. The new $1 billion authorization announced in October signaled extreme confidence and provided support for earnings per share.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
October 25, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Medpace Q3 2026 Earnings Transcript
  2. Medpace Q2 2026 Form 10-Q
08 Explore the industry

Comparable Diagnostics & Research companies

Companies near Medpace Holdings, Inc. in Finn's Diagnostics & Research industry ranking.

Get started with Finn today